Key result
Hancock porcine bioprosthetic valves demonstrate ~6% operative mortality and low thromboembolism rates.
Why the study?
Long-term clinical experience and durability data for the Hancock porcine bioprosthetic heart valve were needed to assess survival, thromboemboli, and valve function.
What are the long-term survival, thromboembolic risk, and durability of the Hancock porcine bioprosthetic heart valve?
Population
467 patients receiving 528 Hancock porcine bioprosthetic heart valves
Design
Cohort study
Follow-up
Average 33 months (range 16-75 months)
Authors
Loading...
Supports durability data for Hancock valve in non-AF patients; extends observational reports but leaves open randomized comparisons.
Cohort (n=467)
What are the long-term survival, thromboembolic risk, and durability of the Hancock porcine bioprosthetic heart valve?
The Hancock porcine bioprosthetic heart valve demonstrates acceptable durability over 6 years with a low incidence of thromboemboli in patients without chronic atrial fibrillation.
Cohen et al. (1979) conducted a cohort in Valvular heart disease requiring valve replacement (n=467). Hancock porcine bioprosthetic heart valve was evaluated on Overall operative mortality. The Hancock porcine bioprosthetic heart valve demonstrated an overall operative mortality of 5.6% and actuarial survival of 75.7% to 79% at 66-75 months, with a low incidence of thromboemboli.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: